title: Hypoxia-related protein expression and its clinicopathologic implication in carcinoma of unknown primary.
abstract: Carcinoma of unknown primary (CUP) is a heterogeneous entity with different clinical and histological features. The aim of this study was to investigate the clinicopathological features and expression of proteins associated with carcinogenesis and tumor environment in different histological subtypes of CUP. Sixty-nine cases of CUP were subjected to immunohistochemistry for EGFR, phospho-EGFR, HER-2, phospho-HER-2, p53, ERCC1, RRM1, REDD1, HIF1α, COX-2, GLUT-1, 14-3-3σ, Phospho-mTOR, Phospho-S6, AMPKα1, Phospho-Akt, PDGF-β receptor, and caveolin-1, and fluorescence in situ hybridization for HER-2 gene amplification. Fourteen (20.3%) cases were poorly differentiated carcinoma, 24 (34.8%) were adenocarcinoma (AD), 17 (24.6%) were squamous cell carcinoma (SC), and 14 (20.3%) were undifferentiated carcinoma (UD). AD were mostly carcinomatosis type, while SC and UD were mostly nodal type (p < 0.001). SC showed more frequent EGFR overexpression (p < 0.001) and Glut-1 (p = 0.001). AD (p = 0.001) and carcinomatosis (p < 0.001) types showed shorter overall survival. SCs expressing Glut-1, HIF1α, and COX2 showed a poor prognosis (p = 0.048, 0.029, and 0.042, respectively). CUP shows various clinicopathological features according to the histological subtypes. SC is mainly associated with nodal metastasis in the head and neck, and frequent EGFR overexpression and Glut-1 expression. Glut-1, HIF1α, and COX2 expression in SC is associated with a poor prognosis.
authors: Department of Pathology, Yonsei University Health System, 250 Seongsan-ro, Seodaemun-gu, Seoul, South Korea.
authors: Ja Seung
authors: JS
authors: Koo
authors: Haeryoung
authors: H
authors: Kim
references: Anticancer Res. 1995 Nov-Dec;15(6B):2563-7
references: 8669824
references: Eur J Cancer. 2002 Feb;38(3):409-13
references: 11818207
references: Cancer. 2003 Mar 15;97(6):1573-81
references: 12627523
references: Eur J Cancer. 2002 Sep;38(13):1810-2
references: 12175699
references: J Clin Oncol. 2000 Feb;18(3):632-5
references: 10653878
references: Scand J Gastroenterol. 2009;44(9):1101-8
references: 19606394
references: Cancer Res. 2006 Jul 1;66(13):6683-91
references: 16818642
references: Thorax. 2009 Dec;64(12):1082-9
references: 19778933
references: Oncol Rep. 2008 Dec;20(6):1381-5
references: 19020718
references: Nat Rev Cancer. 2008 Sep;8(9):705-13
references: 19143055
references: Histol Histopathol. 2009 Feb;24(2):175-85
references: 19085834
references: Curr Probl Cancer. 1979 Nov;4(5):4-37
references: 391494
references: Oral Oncol. 2007 Apr;43(4):373-8
references: 16979927
references: Cancer Res Treat. 2007 Sep;39(3):109-15
references: 19746220
references: Acta Oncol. 2005;44(2):155-60
references: 15788295
references: Cancer Treat Rev. 2006 Dec;32(8):637-44
references: 17046164
references: Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009 Jan;44(1):57-62
references: 19484991
references: Jpn J Clin Oncol. 2007 Dec;37(12):955-60
references: 18211986
references: Clin Cancer Res. 2002 Jun;8(6):1831-7
references: 12060624
references: Cancer Lett. 2009 Apr 18;276(2):125-35
references: 18790562
references: Int J Cancer. 2007 Apr 1;120(7):1451-8
references: 17245699
references: Curr Probl Cancer. 1988 Jan-Feb;12(1):5-58
references: 3067982
references: Med Clin North Am. 1996 Jan;80(1):153-71
references: 8569295
references: Crit Rev Oncol Hematol. 2005 Jun;54(3):243-50
references: 15890271
references: FEBS J. 2007 Mar;274(6):1393-418
references: 17302740
references: Nat Rev Cancer. 2008 Jan;8(1):56-61
references: 18059462
references: J Clin Oncol. 2007 Jan 1;25(1):118-45
references: 17159189
references: Ann Diagn Pathol. 2010 Feb;14(1):23-9
references: 20123453
references: Ann Oncol. 2003 Feb;14(2):191-6
references: 12562643
references: Cancer Res. 2006 Jan 1;66(1):143-50
references: 16397226